Double maintains 1 strategies that include KURA - Kura Oncology, Inc.
Current Value
$6.561 Year Return
Current Value
$6.561 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -26.47% | $414.68M | 1.43% |
VIXY | -24.49% | $195.31M | 0.85% |
WTMF | -21.99% | $156.99M | 0.65% |
TAIL | -16.84% | $86.59M | 0.59% |
UUP | -15.00% | $325.55M | 0.77% |
USDU | -14.19% | $207.14M | 0.5% |
CTA | -13.96% | $964.37M | 0.76% |
DBE | -8.05% | $55.82M | 0.77% |
UNG | -6.39% | $420.93M | 1.06% |
BNO | -6.16% | $98.06M | 1% |
USO | -5.82% | $976.42M | 0.6% |
DBO | -5.73% | $202.31M | 0.77% |
KMLM | -5.63% | $221.29M | 0.9% |
TBIL | -5.32% | $5.35B | 0.15% |
VRIG | -5.28% | $1.44B | 0.3% |
CCOR | -5.14% | $64.32M | 1.18% |
JAAA | -4.34% | $21.32B | 0.21% |
XLU | -4.06% | $17.96B | 0.09% |
GSG | -3.84% | $1.05B | 0.75% |
OILK | -3.62% | $67.99M | 0.69% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FXY | 0.05% | $548.86M | 0.4% |
WEAT | 0.17% | $115.01M | 0.28% |
IBMO | 0.21% | $506.25M | 0.18% |
BIL | 0.28% | $41.05B | 0.1356% |
USFR | 0.31% | $18.50B | 0.15% |
ICLO | -0.32% | $354.66M | 0.2% |
TFLO | 0.38% | $6.78B | 0.15% |
FXU | 0.40% | $1.50B | 0.64% |
TUR | -0.52% | $184.96M | 0.59% |
KRBN | -0.54% | $172.14M | 0.85% |
FTGC | 0.65% | $2.51B | 1.02% |
XBIL | 0.65% | $708.50M | 0.15% |
AFIF | -0.67% | $135.76M | 1.11% |
AGZD | -0.76% | $136.57M | 0.23% |
KBA | -0.78% | $189.13M | 0.56% |
EQLS | 0.79% | $4.77M | 1% |
FTXG | 0.79% | $25.99M | 0.6% |
CARY | 0.80% | $347.36M | 0.8% |
ASHR | -0.83% | $2.63B | 0.65% |
EMLP | 0.87% | $3.28B | 0.96% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SNOW | -25.59% | $49.96B | -4.26% | 0.00% |
CRNC | -19.23% | $340.84M | -47.08% | 0.00% |
LITB | -11.71% | $41.37M | -43.18% | 0.00% |
CBOE | -11.07% | $23.56B | +23.21% | 1.08% |
WEC | -10.92% | $34.39B | +32.97% | 3.11% |
AOSL | -10.74% | $732.73M | +14.53% | 0.00% |
EXC | -10.38% | $46.36B | +22.19% | 3.35% |
PULM | -9.57% | $22.41M | +258.77% | 0.00% |
UTI | -9.52% | $1.41B | +76.07% | 0.00% |
D | -8.80% | $47.94B | +15.48% | 4.74% |
ALL | -8.43% | $54.99B | +20.26% | 1.82% |
AEP | -8.04% | $57.87B | +27.18% | 3.33% |
ED | -8.03% | $38.86B | +21.48% | 3.03% |
DE | -7.46% | $129.86B | +18.43% | 1.30% |
PGR | -7.42% | $166.65B | +35.36% | 1.73% |
KD | -7.31% | $7.48B | +49.26% | 0.00% |
VSTS | -7.27% | $1.27B | -48.42% | 1.46% |
DTM | -7.12% | $9.96B | +56.03% | 3.15% |
K | -6.97% | $28.48B | +43.06% | 2.75% |
AEE | -6.96% | $27.20B | +36.41% | 2.69% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CPRJ | 57.89% | $48.36M | 0.69% |
RSPA | 52.29% | $292.30M | 0% |
QQA | 46.99% | $172.76M | 0% |
XBI | 45.37% | $5.07B | 0.35% |
GNOM | 40.36% | $48.63M | 0.5% |
ARKG | 39.23% | $963.54M | 0.75% |
IBB | 37.42% | $5.74B | 0.45% |
CPSJ | 36.18% | $32.86M | 0.69% |
IWC | 35.77% | $799.66M | 0.6% |
QETH | 34.13% | $13.73M | 0.25% |
CETH | 34.01% | $8.44M | 0% |
PINK | 33.80% | $141.58M | 0.5% |
FETH | 33.78% | $733.92M | 0.25% |
ETHV | 33.77% | $84.73M | 0% |
EZET | 33.70% | $21.63M | 0% |
ARKK | 33.15% | $5.02B | 0.75% |
EFAA | 32.50% | $99.75M | 0% |
VTWO | 31.95% | $10.85B | 0.07% |
IWM | 31.81% | $63.34B | 0.19% |
KJUL | 31.37% | $155.04M | 0.79% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MKC | 0.05% | $22.06B | +5.09% | 2.07% |
GRND | -0.05% | $3.85B | +76.70% | 0.00% |
CME | -0.06% | $94.51B | +22.09% | 3.99% |
VNET | -0.06% | $2.06B | +335.36% | 0.00% |
CLMT | 0.11% | $1.10B | -14.10% | 0.00% |
GOLF | -0.13% | $4.06B | +3.41% | 1.31% |
CNA | 0.14% | $13.75B | +20.86% | 3.54% |
RPRX | -0.15% | $13.51B | +5.88% | 2.73% |
NOMD | 0.16% | $3.01B | +3.37% | 3.17% |
BF.A | 0.18% | $15.61B | -36.74% | 2.70% |
UFCS | 0.19% | $752.56M | +38.36% | 2.20% |
JNJ | 0.20% | $369.31B | -2.84% | 3.22% |
SYY | 0.20% | $36.90B | -6.23% | 2.69% |
IBM | 0.21% | $232.13B | +32.54% | 2.70% |
GOGO | -0.23% | $1.11B | +0.72% | 0.00% |
CRGY | 0.24% | $2.13B | -2.21% | 4.40% |
CCEP | 0.26% | $40.17B | +26.40% | 2.41% |
ADM | 0.27% | $23.15B | -23.11% | 4.18% |
BDX | -0.27% | $64.90B | -6.22% | 1.77% |
EW | -0.28% | $42.10B | -23.79% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CATX | 50.35% | $145.14M | -86.58% | 0.00% |
ZYME | 43.49% | $815.11M | +25.89% | 0.00% |
FATE | 41.10% | $86.76M | -88.87% | 0.00% |
CPA | 40.33% | $3.79B | -12.04% | 7.14% |
KYMR | 37.40% | $1.64B | -32.96% | 0.00% |
APGE | 37.23% | $2.12B | -40.55% | 0.00% |
SUNS | 36.50% | $146.29M | -3.54% | 8.38% |
RGNX | 36.44% | $338.58M | -66.68% | 0.00% |
ARWR | 36.23% | $1.68B | -53.40% | 0.00% |
ATXS | 35.72% | $304.74M | -57.81% | 0.00% |
IMNM | 35.59% | $544.31M | -70.73% | 0.00% |
CLDX | 35.16% | $1.12B | -59.06% | 0.00% |
MMS | 34.97% | $3.89B | -14.99% | 1.76% |
SHC | 34.49% | $3.16B | -2.20% | 0.00% |
RCKT | 34.38% | $619.52M | -77.39% | 0.00% |
RXRX | 34.30% | $2.05B | -41.90% | 0.00% |
CRSP | 33.81% | $2.84B | -49.04% | 0.00% |
BEAM | 33.53% | $1.76B | -42.28% | 0.00% |
GBIO | 33.51% | $24.67M | -91.04% | 0.00% |
RCUS | 33.47% | $816.03M | -56.49% | 0.00% |
Yahoo
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Stifel 2025 Virtual Targeted Oncology Forum. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 10:30 a.m. ET / 7:30 a.m. PT on April 8, 2025. A live audio webcast of the fire
Yahoo
– Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and cabozantinib in patients with RCC in 2H 2025 – SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that an abstract contain
Yahoo
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 3, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 190,000 shares of common stock to six (6) new employees unde
SeekingAlpha
Kura Oncology's (KURA) ziftomenib shows AML promise amid competition. See why I'm inclined to view the current price levels as a tentatively optimistic buy-in point.
Yahoo
Even the best stock pickers will make plenty of bad investments. Anyone who held Kura Oncology, Inc. ( NASDAQ:KURA...
Yahoo
Q4 2024 Kura Oncology Inc Earnings Call